Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: John M. who wrote (10320)	6/10/1999 10:16:00 AM
From: RCJIII	Read Replies (1) \| Respond to of 52051

This is big, everyone check out this news- NERX- (BSNS WIRE) NeoRx's Pretarget-Lymphoma Produces Tumor Regressions, Inclu NeoRx's Pretarget-Lymphoma Produces Tumor Regressions, Including Complete Responses; Data Selected for 'Highest Grade' in Therapeutic Oncology at Society of Nuclear Medicine Business Editors LOS ANGELES--(BUSINESS WIRE)--June 10, 1999--Dr. Hazel Breitz, Virginia Mason Medical Center (Seattle, WA), reported at the Society of Nuclear Medicine meeting that NeoRx Corporation's (Nasdaq:NERX) Pretarget(R) technology permitted the safe administration of higher radiation doses to lymphoma patients than conventional radioimmunotherapy, and that patients receiving these doses experienced substantial tumor regressions including complete responses in some cases. The maximum tolerated dose has not yet been reached. The abstract describing this work received the highest grade in the category of Therapeutic Oncology at the meeting. "Both dosimetry calculations and the patients' tolerance and responses provide proof-of-concept that Pretarget technology may provide substantial benefits to lymphoma patients, even some who have had extensive prior therapies such as bone marrow transplantation," said Dr. Breitz. The Pretarget technology employed involves first injecting a tumor-directed antibody carrying a receptor to the tumor, followed by a clearing step to remove the receptor from circulation. The radiation is then injected on a small molecule carrier that rapidly targets the receptor on the tumor, with most of the remaining radiation being quickly excreted from the body. By contrast, conventional approaches attach the radiation to the antibody that circulates throughout the body for a sustained period, increasing the radiation exposure to normal organs such as bone marrow. Patients involved in this proof-of-concept study included both intermediate and low-grade lymphoma patients, most of whose tumors had grown again after extensive prior therapies. Three patients had received high dose therapy requiring bone marrow transplantation; other patients had bone marrow that was extensively involved with tumor. "It is remarkable, but not surprising, that even these patients tolerated these high doses well, and it is particularly gratifying that one of the complete responses was achieved in a patient who had received a prior stem cell transplant," said Paul Abrams, M.D., J.D, NeoRx's Chief Executive Officer. "That is what this work is all about. Although this study was conducted with a commercially-available lymphoma antibody, NeoRx has now constructed its own proprietary molecule designed to improve binding to lymphoma cells and that may result in reduced manufacturing lead times and costs." NeoRx Corporation is developing innovative products designed to provide improved, cost-effective treatments for patients with cancer and inflammatory diseases. This release contains forward-looking statements relating to the development of the Company's products and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "may," "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include the progress and costs of clinical trials and the timing of regulatory approvals. Reference is made to the Company's latest Annual Report on Form 10 - K filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Visit NeoRx at www.neorx.com. To receive NeoRx news releases via email, register at www.neorx.com/news/pr.html. NeoRx and Pretarget are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries. (c) 1999 NeoRx Corporation. All Rights Reserved. --30--APS/se* CONTACT: NeoRx Melinda Kile, 206/286-2508 Controller KEYWORD: WASHINGTON CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICALS MEDICINE BIOTECHNOLOGY Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *